Press Release
Schindellegi, Switzerland, October 20th, 2024
We are pleased to announce that Dr. Philippe Gadal is joining Zynnon as an Advisor, where he will contribute his expertise and leadership to enhance our Scientific Advisory Board.
As the former CEO of AES Chemunex US, General Manager of Diagnostica Stago Inc., Deputy Industry Sales and Marketing for North America at bioMérieux Inc, US Director of Hematology at Roche Diagnostics, President of ABX US, and CEO of Trinity biotech US — all positions held in the USA — he has had the opportunity to introduce new technologies in both Clinical and Industrial markets on a global scale.
Dr. Gadal is a pharmacist and an experienced regulatory intelligence advisor with over 20 years of strategic leadership in sales and marketing, specializing in the USA, Europe, and Asia. As a member of the Regulatory Governance team at BioPhorum, an association of more than 53 global biopharmaceutical manufacturers and suppliers, he brings extensive expertise. He also has significant experience working directly with the FDA on sterility testing validation programs within compounding pharmacies.
Khaled Abousaleh, CEO of Zynnon comments: “We are deeply honored to welcome Dr. Philippe Gadal in our team. His remarkable background in regulatory intelligence, Sales, and — particularly within the U.S. market — combined with his extensive expertise in industrial microbiology and diagnostics, will undoubtedly be a tremendous asset. We are looking forward to collaborating with him and are confident that this partnership will be successful and rewarding. His contributions will be instrumental in driving our future advancements and market launches.”
Dr. Philippe Gadal states: “I’m excited to support Zynnon’s innovative project, which utilizes a biomarker-based approach for detecting Volatile Organic Compounds (VOCs) to quickly and accurately identify bacterial and fungal pathogens. This innovative system promises to greatly improve diagnostic accuracy and speed, which is crucial for effectively treating infections like sepsis. It aligns with strategies to combat Antimicrobial Resistance (AMR) by improving how pathogens are detected and identified in clinical settings. This technology will also initiate a new era for the industrial microbiology market, enabling rapid and continuous sterility testing throughout the process. My experience with Zynnon has shown me the impressive potential of their VOC-detection technology, leading me to join their board of advisors.”
About Zynnon
Zynnon (www.zynnon.com) is a startup transforming infectious pathogen diagnostics, minimizing operations within the laboratory and speeding up the transmission of vital pathogen information to the treating physician in order to optimize treatments and improve patient outcomes. This gaseous biomarker-based solution for the detection of Volatile Organic Compounds (“VOCs”) is used to rapidly and precisely identify bacterial and fungal pathogens to the genus and species level. The VOC-detection and differentiation technology serves as a rapid and efficient alternative or add-on to traditional pathogen identification laboratory methods, substantially shortening the timeline from sample collection to actionable lab results. By streamlining complex procedures into a simple, small, compact, and easy-to-operate sensor-based VOC detector, along with a validated VOC database, the need for specialized laboratory skills for pathogen detection and classification (such as PCR and/or immunoassay-based techniques) is eliminated.
Disclaimer : Not CE-marked, not FDA approved. Product not available on the market, not for sale.
For media inquiries and additional information, please contact:
Alex Marc
CFO & Investor Relations Manager
Zynnon AG
Phone: +41 79 455 40 30
Email: alex.marc@zynnon.com